Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
|Articles|June 1, 1999
Supplements and Featured Publications
- Clinical and Economic Impact of Breast Cancer Treatment and Prevention in High-Risk Women
- Volume 5
- Issue 6 Suppl
Breast Cancer Stage Cost Analysis in a Managed Care Population
Author(s)Kenneth L. McDonough, MD
Advertisement
Articles in this issue
over 27 years ago
Participating Facultyover 27 years ago
Benefits Foregone: Too Much of the Wrong and Too Little of the Rightover 27 years ago
Breast Cancer Epidemiology: An Overviewover 27 years ago
Overview of Cancer Economicsover 27 years ago
Question-and-Answer Sessionover 27 years ago
Selected AbstractsAdvertisement
Related to this article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5